95,96 Durvalumab stimulates the immune system and may cause it to attack healthy organs and tissues. For adults with unresectable Stage 3 non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent chemoradiation therapy (CRT). More About Durvalumab ... actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the … Felt bit tired this afternoon exactly 24 hours after the infusion other than that if Wednesday is good with no side effects piece cake. Side effects range from mild to severe. They may occur during your treatment, or after your treatment has ended. a reaction to durvulumab that happens on the day of the infusion or the day after – this might include a red, itchy rash (hives) Lung problems: cough, shortness of breath, and chest pain, Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; and severe stomach-area (abdomen) pain or tenderness, Liver problems: yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of For the full list of side effects and restrictions of Imfinzi, see the package leaflet. SIDE EFFECTS: The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. While on IMFINZI, you may experience side effects. Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with. More About Durvalumab ... actions, interactions, or side effects of this drug, or precautions to be taken while using it. Talk to your healthcare provider about birth control methods that you can use during this time. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Tell your doctor if you have any side effects that bother you or that do not go away. Medically reviewed by Drugs.com. This is not a complete list of durvalumab side effects. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. 2. Not hungry. Ask your doctor or pharmacist for more information. The most common side effects with Imfinzi (which may affect more than 1 in 5 people) are cough, nose and throat infections, and rash. Side Effects Warnings and Interactions One of a class of drugs called checkpoint inhibitors, Imfinzi (generically known as durvalumab) is used to take on certain forms of lung and bladder cancer that have started to spread. This phase I trial studies the side effects of durvalumab, tremelimumab, and radiation therapy in treating patients with gynecologic cancer that has spread to other places in the body or cannot be removed by surgery. Because durvalumab enhances your immune system response to cancer, it may cause unintended side effects that are caused by the immune system and affect healthy cells as well. Last updated on Sep 21, 2020. This is not a complete list of side effects and others may occur. Immunotherapy can affect many parts of your body. The active substance in Imfinzi, durvalumab, is a monoclonal antibody, a type of protein designed to recognise and attach to a protein called ‘programmed death-ligand 1’ (PD-L1), which is present on the surface of many cancer cells.. PD-L1 acts to switch off immune cells that would otherwise attack the cancer cells. These are not all the possible side effects of IMFINZI. Getting medical treatment right away may help keep these problems from becoming more serious. Signs and symptoms of infusion reactions may include: chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness, feel like passing out, fever, and back or neck pain, Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). Durvalumab (Imfinzi) These drugs have also been shown to be helpful in treating different types of cancer, and are being studied for use against others. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with IMFINZI. This is because IMFINZI can cause your immune system to attack normal organs and tissues and can affect the way they work. If your doctor has directed you to use this medication , your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Durvalumab side effects . IMFINZI can cause serious side effects (see above): The most common side effects in people with non-small cell lung cancer (NSCLC) include cough, feeling tired, inflammation in the lungs, upper respiratory tract infections, shortness of breath, and rash. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Call your doctor for medical advice about side effects. What Other Drugs Interact with Durvalumab? Before you receive IMFINZI, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, severe and fatal immune-mediated reactions. Applies to durvalumab: intravenous solution. Adverse side effects seen in animal reproductive studies. severe and fatal immune-mediated reactions. unusual or easy bruising or bleeding Side effect(s) of Durvalumab Read the side effects of Durvalumab as described in the medical literature. Tiredness, loss of appetite, nausea, constipation, muscle/bone pain, or swelling hands/ ankles /feet may occur. … locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy; or; who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. IMFINZI is a registered trademark and AstraZeneca Access 360 is a trademark of the AstraZeneca group of companies. It is an irritation of the lungs and needs to be treated with steroids. Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with. Durvalumab causes your immune system to attack tumor cells, but it could also attack healthy organs and tissues in your body. • Other drugs may . Common side effects may include: nausea, constipation; decreased appetite; feeling weak or tired; bone or muscle pain; cough, feeling short of breath; cold symptoms such as stuffy nose, sneezing, sore throat; painful urination; hair loss; rash; or swelling in your arms and legs. Some side effects of durvalumab may occur that usually do not need medical attention. This could lead to … ended. Upset stomach. Call your doctor for medical advice about side effects. Immune-mediated reactions , including pneumonitis, hepatitis, colitis, endocrinopathies, nephritis and rash , … These side effects may go away during treatment as your body adjusts to the medicine. Durvalumab Side Effects. Ask your healthcare provider or pharmacist for more information. Ask your doctor or pharmacist for more information. treatment may be changed based on the test results and/or other side effects. If you notice any other effects, check with your healthcare professional. Both durvalumab and tremelimumab have been tested for mesothelioma alone, but not in combination. Immune-mediated reactions , including pneumonitis, hepatitis, colitis, endocrinopathies, nephritis and rash , have been reported and may be severe. Do not breastfeed during treatment and for at least 3 months after the last dose of IMFINZI. Please see Important Safety Information below and complete Prescribing Information. Your patient alert card. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include: Chest pain, irregular heartbeats, shortness of breath or swelling of ankles; confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs; double vision, blurry vision, sensitivity to light, eyepain, changes in eyesight; persistent or severe muscle pain or weakness, muscle cramps; and low red blood cells, bruising, Infusion reactions that can sometimes be severe or life-threatening. Getting medical treatment right away may help keep these problems from becoming more serious. If the side effects are severe, your doctor might delay giving the checkpoint inhibitor for a period of time to allow the body to recover. Your doctor, nurse or pharmacist will give you a card with information about your treatment on it. Side Effects of Durvalumab Due to the effects of durvalumab on the immune system, many patients taking the immunotherapy medication experience physical side effects. Some organs that can be affected include the thyroid, pituitary gland, adrenal glands, pancreas, gastrointestinal tract, liver, lungs, skin, kidneys, and others. Some side effects can cause severe or life threatening conditions, so even mild side effects must be taken seriously and reported immediately. Muscle pain. US-33919; US-47125; US-45120; US-49291 Last Updated 2/21, a type of lung cancer called non-small cell lung cancer (NSCLC). Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. NSCLC is now known to be an immunologically targetable cancer. Your healthcare provider may also need to delay or completely stop treatment with IMFINZI if you have severe side effects. Some side effects can cause severe or life threatening conditions, so even mild side effects must be taken seriously and reported immediately. While on IMFINZI, you may experience side effects. This could lead to serious or life-threatening side effects on your lungs, liver, pancreas, kidneys, intestines, thyroid, or adrenal glands. SIDE EFFECTS: The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). This could lead to serious or life-threatening side effects on your lungs, liver, pancreas, kidneys, intestines, thyroid, or adrenal glands. Tell your healthcare provider about all the medicines you take, The most common side effects in people with non-small cell lung cancer (NSCLC), have immune system problems such as Crohn's disease, ulcerative colitis, or lupus, have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic), have received radiation treatment to your chest area, have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome, are pregnant or plan to become pregnant. Developed by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that acts to promote natural immune responses that destroy tumour cells. IMFINZI® (durvalumab) is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). You may report side effects to FDA at 1-800-FDA-1088. Less common side effects of durvalumab include: Cough; Anemia, grades 3-4; Infusion-related reactions, grades 3-4; Increased alkaline phosphatase, grades 3-4; Hypermagnesemia, grades 3-4; Hypercalcemia, grades 3-4; Hyperglycemia, grades 3-4; Immune-mediated pneumonitis or ILD; Increased AST, grades 3-4; Immune-mediated hepatitis; Increased ALT, grades 3-4 In case of any doubt consult your doctor or pharmacist. All drugs may cause side effects. interact: with durvalumab. Monitor patients for signs and symptoms of hepatitis during and after discontinuation of IMFINZI, including clinical chemistry monitoring. You may report side effects to the FDA at 1-800-FDA-1088. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Your healthcare provider will monitor you for these complications. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. For the full list of side effects and restrictions of Imfinzi, see the package leaflet. With proper treatment, the side effects can resolve in one to three weeks. Hi jese80 I too am on Durvalumab, there is a thread here on Inspire created by a nice ma called Eric his screen name is (peaceborro) it's under Treatment Options but when it was started it was spelled Duravalumab, it was a really active group, but I think I am the only person who posts in there now lol! You may report side effects to the FDA at 1-800-FDA-1088. Durvalumab is also being studied in the treatment of other types of cancer. Durvalumab is a monoclonal human immunoglobulin G1 kappa (IgG1k) antibody that selectively inhibits the binding to PD-1 and CD801 of programmed cell death ligand-1 (PD-L1) (B7.1). Please click here for complete Prescribing Information, including Patient Information (Medication Guide). Astra-Zeneca Pharmaceuticals, Wilmington, DE. See Full Indication ». Call your doctor for medical advice about side effects. Durvalumab may have the following side effects: Rash; Type 1 diabetes mellitus; UTI; Thyroiditis; Hypothyroidism; Keratitis; Uveitis; Increased serum creatinine; Elevation of ALT/AST levels; Serum bilirubin increased; Rarely, immune-mediated aseptic meningitis; Hemolytic anemia; Thrombocytopenia; Myocarditis; Myositis; Hypophysitis; Hypopituitarism leading to adrenal insufficiency